PO No :PO1661766446-201

Name	: Ms.TANYA	Client Name	: 1 MG INTEGRATION - GURUGRAM
Age/Gender	: 33/Female	Registration Date	: 08/Feb/2025 02:43PM
Patient ID	: 1MG605205	Collection Date	: 08/Feb/2025 01:05PM
Barcode ID/Order ID	: D16591883 / 11925931	Report Date	: 10/Feb/2025 04:31PM
Referred By	: Dr.	Report Status	: Final Report
Sample Type	: Serum		

IMMUNOLOGY

Test Name	Result	Unit	Bio. Ref. Interval	Method
Dual Marker Test				
Free Beta HCG	25.80	ng/mL		CLIA
PAPP-A (Pregnancy Associated Plasma Protein)	3.010	mIU/mL		CLIA

Comment:

*Graph enclosed-**Maternal Serum Screen [Dual Marker]First trimester**
Result relate only to the sample, as received
The calculated risk by PRISCA depends on the accuracy of the information provided by the referring Physician.
All software may not give similar risk factor for the similar data

DISORDER	SCREEN POSITIVE CUT OFF
Trisomy 21 (Down)	1:250
Trisomy 18/13	1:100

* **This is a screening test,not a diagnostic test.**This risk assessment report is based in part on demographic data provided by the ordering Physician.Please notify the laboratory promptly if any data is incorrect.
*It is Statistical risk factor calculation for Trisomy 21 (Down's syndrome), Trisomy 18 (Edward Syndrome) and Trisomy 13 using CE marked PRISCA 5.1 software.
*Screening tests are based on statistical analysis of patient demographic and biochemical data. They simply indicate a high or low risk category. The interpretive unit is MoM (Multiples of Median) which takes into account variables such as gestational age (ultrasound), maternal weight, race, insulin dependent Diabetes, multiple gestation, IVF (Date of Birth of Donor, if applicable), smoking & previous history of Down syndrome. **Accurate availability of this data for Risk Calculation is critical.** ·
*Ideally all pregnant women should be screened for Prenatal disorders irrespective of maternal age. The test is valid between 9-13.6 weeks of gestation, but **ideal sampling time is between 11-13 weeks gestation.**
* First trimester detection rate of Down syndrome is 60% with a false positive rate of 5%. A combination of Nuchal translucency, Nasal bone visualization and biochemical tests (Combined test) increases the detection rate of Down syndrome to 85% at the same false positive rate.
*Statistical evaluation enclosed being more informative ,the reference ranges for the biochemical parameters are not quoted on the report.
*In case of CRL below 38mm,CRL & NT are not taken for calculation .
*Screening cutoffs are established by using MoM values that maximize the detection rate and minimize false positives.
* CLIA : Chemiluminescence Immunoassy.

***** End Of Report *****

Conditions of Laboratory Testing & Reporting:
Test results released pertain to the sample, as received. Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the interpreting clinician. Result delays may happen because of unforeseen or uncontrollable circumstances. Test report

NABL certificate and scope

MC - 5424

This test has been performed at
TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I, Okhla Industrial Estate, New Delhi, Delhi 110020

Dr. Kundan Kumar
MBBS, MD (Lab Medicine)
Consultant Laboratory Medicine
Reg No- 96030

Scan for digital copy

PO No :PO1661766446-201

Name	: Ms.TANYA	Client Name	: 1 MG INTEGRATION - GURUGRAM
Age/Gender	: 33/Female	Registration Date	: 08/Feb/2025 02:43PM
Patient ID	: 1MG605205	Collection Date	: 08/Feb/2025 01:05PM
Barcode ID/Order ID	: D16591883 / 11925931	Report Date	: 10/Feb/2025 04:31PM
Referred By	: Dr.	Report Status	: Final Report
Sample Type	: Serum		

IMMUNOLOGY

Test Name	Result	Unit	Bio. Ref. Interval	Method

may vary depending on the assay method used. Test results may show inter-laboratory variations. Test results are not valid for medico-legal purposes. Please mail your queries related to test results to Customer Care mall ID care@1mg.com

Disclaimer: Results relate only to the sample received. Test results marked "BOLD" indicate abnormal results i.e. higher or lower than normal. All lab test results are subject to clinical interpretation by a qualified medical professional. This report cannot be used for any medico-legal purposes. Partial reproduction of the test results is not permitted. Also, TATA 1mg Labs is not responsible for any misinterpretation or misuse of the information. The test reports alone may not be conclusive of the disease/condition, hence clinical correlation is necessary. Reports should be vetted by a qualified doctor only.

NABL certificate and scope

MC - 5424

This test has been performed at
TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I, Okhla Industrial Estate, New Delhi, Delhi 110020

Dr. Kundan Kumar
MBBS, MD (Lab Medicine)
Consultant Laboratory Medicine
Reg No- 96030

Scan for digital copy

TATA 1mg Technologies Pvt. Ltd.
2nd Floor, B-225, Okhla Industrial Area, Phase-1
New Delhi-110020

Prisca 5.2.0.13

Date of report: 10/02/25

Patient data

Name	Ms.TANYA	Patient ID	1MG605205
Birthday	22/05/91	Sample ID	D16591883
Age at delivery	34.3	Sample Date	08/02/25
Gestational age	12 + 1		

Correction factors

Fetuses	1	IVF	no	Previous trisomy 21 pregnancies	no
Weight	74	diabetes	no		
Smoker	no	Origin	Asian		

Biochemical data

Parameter	Value	Corr. MoM
PAPP-A	3.01 mIU/ml	1.26
fb-hCG	25.8 ng/ml	0.72

Risks at term

Age risk	1:497
Biochemical T21 risk	<1:10000
Combined trisomy 21 risk	<1:10000
Trisomy 13/18 + NT	<1:10000

Ultrasound data

Gestational age	12 + 0
Method	CRL Robinson
Scan date	07/02/25
Crown rump length in mm	56.9
Nuchal translucency MoM	1.20
Nasal bone	present
Sonographer	DR NA
Qualifications in measuring NT	NA



Trisomy 21

The calculated risk for Trisomy 21 (with nuchal translucency) is below the cut off, which indicates a low risk.
After the result of the Trisomy 21 test (with NT) it is expected that among more than 10000 women with the same data, there is one woman with a trisomy 21 pregnancy.
The calculated risk by PRISCA depends on the accuracy of the information provided by the referring physician.
Please note that risk calculations are statistical approaches and have no diagnostic value!
The patient combined risk presumes the NT measurement was done according to accepted guidelines (Prenat Diagn 18: 511-523 (1998)).
The laboratory can not be hold responsible for their impact on the risk assessment ! Calculated risks have no diagnostic value!

Trisomy 13/18 + NT

The calculated risk for trisomy 13/18 (with nuchal translucency) is < 1:10000, which represents a low risk.

Sign of Physician

below cut off | Below Cut Off, but above Age Risk | above cut off

TATA 1mg | Labs

TATA

ENSURING ACCURACY IN EVERY SINGLE REPORT

Following a 3-step review process:

Advanced systems & cutting-edge technology analyze results with precision

Experienced lab experts and technicians conduct comprehensive reviews



Each report undergoes rigorous medical scrutiny & is signed off by a doctor

Have concerns regarding the report?

Reach out to our care team at **care@1mg.com** or **chat with us**

CONNECT NOW >

Accurate Testing, Assured Quality: Diagnostics Precision

Stringent quality control
Measures meeting international norms of safety guidelines

Cutting-edge technology
Robust healthcare systems equipped with calibrated & well-maintained machinery

Experienced lab staff
30+ medical professionals with a collective experience of 200+ years

Verified test procedures
Highly standardized test procedures following CLSI* guidelines

External assessments
Thorough third-party assessment by authorized experts

Trained phlebotomists
Ensuring smooth sample collection experience & pre-analytical precision

Claim FREE doctor consultation

Consult top doctors from the comfort of your home

SCHEDULE NOW>

Watch how we take care of your sample

TATA 1mg CANCER care
Making Strides in Compassionate Care

- Get Second Opinion
- Order Medicines
- Book Lab Tests
- Explore Financial Support & more

EXPLORE NOW >

Need Help?
1800-102-1618

*Clinical & Laboratory Standards Institute

T&C Apply

Are you getting enough **OMEGA 3** to protect your heart?

Because 80%^ of people don't!

Choose Tata 1mg Salmon Omega 3 for a Healthier Heart

- Reduces Triglyceride Levels
- Improves Good Cholesterol
- Reduces Inflammation

Get Optimal Requirement# of Omega 3 in 1 Capsule

EPA	DHA	Fish Oil
180 mg	120 mg	1000 mg

Why Choose Us?

50% Higher Absorption+ with Triglyceride form

50% Lower Saturated Fats*

Every batch Tested and Certified

Upto 30% off

Shop Now

^ Stark KD, et al, progress in Lipid Research 2016 | * Compared with competing products
+ Reference from NCBI published article on comparative bioavailability | # Optimal requirement of Omega-3 as mentioned by National Institutes of Health. Dietary Supplement Label Database. 2015.